Search Results - Magali Pederzoli-Ribeil

568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates by Wilson Guzman, Minjie Zhang, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Hsin-Jung Wu, Hanumantha Rao Madala, Caitlin O’Toole, Magali Pederzoli-Ribeil, Raphael Rozenfeld, Huawei Qiu, Margaret Karow, Tim Clackson, Ronan O’Hagan, Jennifer O’Neil, Ugur Eskiocak

1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models by Wilson Guzman, Damiano Fantini, Parker Johnson, Kurt Jenkins, Hanumantha Rao Madala, Caitlin O’Toole, Magali Pederzoli-Ribeil, Jennifer O’Neil, Jake Taylor, Ekta Patel, Sallyann Vu, Manoussa Fanny, Oleg Yerov, Benjamin Nicholson, Natalia V Malkova, Stephanie Hsiao, Ertan Eryilmaz, Uli Bialucha

719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates by Jia Chen, Wilson Guzman, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Hanumantha Rao Madala, Magali Pederzoli-Ribeil, Huawei Qiu, Ekta Patel, Natalia Malkova, Sallyann Vu, Rebekah O'Donnell, Manoussa Fanny, Oleg Yerov, Caitlin O'Toole, Benjamin Nicholson, Bill Avery, Ronan O'Hagan, Jennifer O'Neil

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer by Zhen Liu, Wilson Guzman, Parker Johnson, Megan McLaughlin, Caitlin O’Toole, Magali Pederzoli-Ribeil, Huawei Qiu, Margaret Karow, Tim Clackson, Jennifer O’Neil, Ugur Eskiocak, Miso Park, Benjamin Nicholson, John C Williams, Kurt A Jenkins, Deborah Moore-Lai, Veronica Flesch, Ronan C O’Hagan, Ulrich Rodeck

Get full text